RxDoctor Payments Data

Marin Nicu, MD

Cardiovascular Disease · Bronx, NYNPI 1942407044

Payments from drug & device makers

$1,100in general payments, 2019–2025

Across 27 payments — averaging $40.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$347
  • Abbott$236
  • Merck$164
  • Abiomed$150
  • Boston Scientific$129
  • Lantheus Medical Imaging, Inc.$57
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,100100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis16$347
Abbott3$236
Merck3$164
Abiomed1$150
Boston Scientific1$129
Lantheus Medical Imaging, Inc.2$57
Amgen1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,100 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$30,273
Medicare patients
331
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$132,845
EntrestoSacubitril/Valsartan126$130,539
JardianceEmpagliflozin86$95,123
FarxigaDapagliflozin Propanediol72$70,928
VerquvoVericiguat49$59,483
XareltoRivaroxaban22$25,052
VascepaIcosapent Ethyl21$16,046
JanuviaSitagliptin Phosphate17$13,612
Atorvastatin Calcium545$7,816
Breo ElliptaFluticasone/Vilanterol11$7,671
Nitroglycerin276$6,222
Ezetimibe242$5,348
Hydralazine Hcl295$3,972
Metoprolol Succinate233$3,842
Isosorbide Dinitrate48$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$347$130,539126 claims
MerckVerquvo, Januvia$164$73,09566 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →